371 related articles for article (PubMed ID: 35455438)
21. Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective.
Nakhlband A; Eskandani M; Omidi Y; Saeedi N; Ghaffari S; Barar J; Garjani A
Bioimpacts; 2018; 8(1):59-75. PubMed ID: 29713603
[No Abstract] [Full Text] [Related]
22. Nanomedicine Approaches for Advanced Diagnosis and Treatment of Atherosclerosis and Related Ischemic Diseases.
Hu B; Boakye-Yiadom KO; Yu W; Yuan ZW; Ho W; Xu X; Zhang XQ
Adv Healthc Mater; 2020 Aug; 9(16):e2000336. PubMed ID: 32597562
[TBL] [Abstract][Full Text] [Related]
23. Nanotheranostics for personalized medicine.
Mura S; Couvreur P
Adv Drug Deliv Rev; 2012 Oct; 64(13):1394-416. PubMed ID: 22728642
[TBL] [Abstract][Full Text] [Related]
24. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
25. Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease.
Zhang Z; Dalan R; Hu Z; Wang JW; Chew NW; Poh KK; Tan RS; Soong TW; Dai Y; Ye L; Chen X
Adv Mater; 2022 Sep; 34(35):e2202169. PubMed ID: 35470476
[TBL] [Abstract][Full Text] [Related]
26. Theranostic nanoparticles for the management of thrombosis.
Russell P; Hagemeyer CE; Esser L; Voelcker NH
Theranostics; 2022; 12(6):2773-2800. PubMed ID: 35401833
[TBL] [Abstract][Full Text] [Related]
27. Challenges in the development of nanoparticle-based imaging agents: Characterization and biology.
Crist RM; Dasa SSK; Liu CH; Clogston JD; Dobrovolskaia MA; Stern ST
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1665. PubMed ID: 32830448
[TBL] [Abstract][Full Text] [Related]
28. Atherosclerosis and Nanomedicine Potential: Current Advances and Future Opportunities.
Jiang F; Zhu Y; Gong C; Wei X
Curr Med Chem; 2020; 27(21):3534-3554. PubMed ID: 30827225
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular therapies utilizing targeted delivery of nanomedicines and aptamers.
Tan KX; Pan S; Jeevanandam J; Danquah MK
Int J Pharm; 2019 Mar; 558():413-425. PubMed ID: 30660748
[TBL] [Abstract][Full Text] [Related]
30. Nanotheranostics and image-guided drug delivery: current concepts and future directions.
Lammers T; Kiessling F; Hennink WE; Storm G
Mol Pharm; 2010 Dec; 7(6):1899-912. PubMed ID: 20822168
[TBL] [Abstract][Full Text] [Related]
31. A Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis.
Bonnet S; Prévot G; Mornet S; Jacobin-Valat MJ; Mousli Y; Hemadou A; Duttine M; Trotier A; Sanchez S; Duonor-Cérutti M; Crauste-Manciet S; Clofent-Sanchez G
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068875
[TBL] [Abstract][Full Text] [Related]
32. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
[TBL] [Abstract][Full Text] [Related]
33. Towards tailored management of malignant brain tumors with nanotheranostics.
Aparicio-Blanco J; Torres-Suárez AI
Acta Biomater; 2018 Jun; 73():52-63. PubMed ID: 29678675
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis.
Hu PP; Luo SX; Fan XQ; Li D; Tong XY
Front Pharmacol; 2022; 13():1000316. PubMed ID: 36160452
[TBL] [Abstract][Full Text] [Related]
35. Current research trends of nanomedicines.
Liu Q; Zou J; Chen Z; He W; Wu W
Acta Pharm Sin B; 2023 Nov; 13(11):4391-4416. PubMed ID: 37969727
[TBL] [Abstract][Full Text] [Related]
36. Cancer-Targeted Nanotheranostics: Recent Advances and Perspectives.
Ma Y; Huang J; Song S; Chen H; Zhang Z
Small; 2016 Sep; 12(36):4936-4954. PubMed ID: 27150247
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches.
Wang W; Huang Z; Huang Y; Zhang X; Huang J; Cui Y; Yue X; Ma C; Fu F; Wang W; Wu C; Pan X
Adv Drug Deliv Rev; 2022 Jun; 185():114309. PubMed ID: 35469997
[TBL] [Abstract][Full Text] [Related]
38. Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching.
Ma S; Motevalli SM; Chen J; Xu MQ; Wang Y; Feng J; Qiu Y; Han D; Fan M; Ding M; Fan L; Guo W; Liang XJ; Cao F
Theranostics; 2018; 8(13):3693-3706. PubMed ID: 30026877
[TBL] [Abstract][Full Text] [Related]
39. Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells.
Kojima R; Aubel D; Fussenegger M
Curr Opin Chem Biol; 2015 Oct; 28():29-38. PubMed ID: 26056952
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
